Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
Century Therapeutics (NASDAQ: IPSC) said its abstracts were accepted for oral presentations at EASD 2026 (Sept 28-Oct 2, Milan) and Breakthrough T1D CRC 2026 (Oct 9-11, Philadelphia). Both will feature preclinical data on CNTY-813, an Allo-Evasion 5.0 engineered iPSC-derived islet therapy for type 1 diabetes, with an IND targeted for Q4 2026.
How this was made
The 30-second read
Why it matters
The release increases scheduled scientific exposure for CNTY-813 and reiterates preclinical themes (glucose-responsive function, safety, scalable manufacturing, immune protection) while keeping the key decision point as the targeted IND submission in Q4 2026.
Market read
This is an event-calendar catalyst for IPSC, but it does not introduce new clinical/regulatory facts or fresh quantitative results.
What to watch
Traders may instead focus on whether Century actually files the IND in Q4 2026 and whether any new preclinical safety or manufacturing details emerge closer to the conference.
Background
Century Therapeutics is developing CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes engineered with Allo-Evasion 5.0 to avoid chronic immunosuppression.
Ticker impact
Century Therapeutics (IPSC) announced CNTY-813 abstracts accepted for oral presentations at EASD 2026 and CRC 2026, highlighting Allo-Evasion 5.0 preclinical work.
Likely limited, with any reaction tied to broader biotech sentiment and expectations for future IND timing rather than immediate fundamentals.
The article is a PR about accepted abstracts and scheduled oral sessions, plus a reiteration that IND submission is targeted for Q4 2026. No new efficacy/safety numbers, IND filing, or trial initiation are disclosed.
Market effects
Adds incremental momentum for iPSC-derived islet replacement therapy narratives and immune-evasion engineering in T1D cell therapy.
Primarily US-listed biotech attention; conference dates may drive periodic retail and small-fund interest.
EASD in Milan provides European visibility, but the release itself is not a global regulatory or clinical breakthrough.
Counterpoint
Abstract acceptance may already be priced in for event-driven traders; without new data, follow-through may be muted.
Key entities
- companyCentury Therapeutics
NASDAQ-listed biotech developing iPSC-derived cell therapies for autoimmune diseases and cancer.
- programCNTY-813
iPSC-derived islet replacement therapy for type 1 diabetes engineered with Allo-Evasion 5.0.
- technologyAllo-Evasion 5.0
Century’s immune evasion engineering intended to enable durable engraftment without chronic systemic immunosuppression.
- conferenceEASD 2026
European Association for the Study of Diabetes annual meeting, Oct 2026 in Milan.
- conferenceBreakthrough T1D Clinical & Research Congress 2026
T1D-focused congress in Philadelphia, Oct 2026.
